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Abstract
Background: Despite limited effectiveness of short-term psychotherapy for chronic depression, there is a lack of
trials of long-term psychotherapy. Our study is the first to determine the effectiveness of controlled long-term
psychodynamic and cognitive-behavioral (CBT) treatments and to assess the effects of preferential vs.
randomized assessment.
Methods/design: Patients are assigned to treatment according to their preference or randomized (if they have no
clear preference). Up to 80 sessions of psychodynamic or psychoanalytically oriented treatments (PAT) or up to
60 sessions of CBT are offered during the first year in the study. After the first year, PAT can be continued according
to the ‘naturalistic’ usual method of treating such patients within the system of German health care (normally from
240 up to 300 sessions over two to three years). CBT therapists may extend their treatment up to 80 sessions, but
focus mainly maintenance and relapse prevention. We plan to recruit a total of 240 patients (60 per arm). A total of
11 assessments are conducted throughout treatment and up to three years after initiation of treatment. The
primary outcome measures are the Quick Inventory of Depressive Symptoms (QIDS, independent clinician rating)
and the Beck Depression Inventory (BDI) after the first year.
Discussion: We combine a naturalistic approach with randomized controlled trials(RCTs)to investigate how
effectively chronic depression can be treated on an outpatient basis by the two forms of treatment reimbursed in
the German healthcare system and we will determine the effects of treatment preference vs. randomization.
Trial registration: http://www.controlled-trials.com/ISRCTN91956346
Keywords: Chronic depression, Cognitive behavioral therapy, Psychodynamic psychotherapy
Background
Based on a recent review, each year 38.2% of the EU
population suffers from a mental disorder. Depression
has been identified as the most disabling disease affect-
ing about 17% of the population during their lifetime
[1]. According to the WHO, depression will be the sec-
ond most frequent illness and will carry the highest load
of impairment of quality of life worldwide in 2020. Par-
ental chronic depression is also a heavy burden for
children [2]. Only 50% of all depressed patients recover
within six months and two-thirds within one year, while
6% to 7% are still depressed after 10 to 15 years. There
is a high danger of a chronic course of depression, as
30% of all episodes of depression last longer than two
years. Half of the patients relapse after their first episode,
70% after the second, and 90% after their third episode
[3]. While medication has evolved as the most frequent
first-line approach to the treatment of depression, 20%
to 30% of patients have not responded to medication;
one-third of those responding relapse within one year,
and 75% relapse within five years.
In more than 80 randomized controlled trials (RCTs),
cognitive behavioral therapy (CBT) has been established
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http://www.trialsjournal.com/content/13/1/117as an effective treatment for depression [4-6]. In a recent
meta-analysis [7] based on 23 studies totaling 1,365 sub-
jects, this could also be established for short-term
psychodynamic psychotherapy (STPP). Compared
with other psychotherapies (usually CBT), a small but
significant effect size (d=−0.30) was found, indicating
the superiority of other psychotherapies immediately
post-treatment, but no significant differences were
found at 3-month (d=−0.05) and 12-month (d=−0.29)
follow-ups.
So far, the evidence for psychotherapy of depression
rests on short-term treatments [6-8]. Unlike the results
for the treatment of acute depression, psychotherapy,
findings of the effects for chronic depression (dysthymia
or major depressive episodes) have been limited [8]. In
addition, short-term treatments offered in randomized
controlled trials lack external validity. Unlike the treat-
ments performed in clinical trials, psychotherapies in
clinical practice throughout Europe are of considerably
longer duration (CBT up to 60 sessions, psychodynamic
treatment up to 80, psychoanalysis up to 240 to 300 ses-
sions). Positive long-term effects of psychoanalysis and
psychoanalytic long-term treatments were shown in a
representative, multi-perspective and retrospective study
[9]. Yet, up until now, there are no controlled studies
available comparing psychoanalysis (PAT) and cognitive
behavior therapy (CBT) directly [10,11]. However, a few
clinical reports [12] comparing psychoanalytic and
cognitive-behavioral long-term therapy exist. They dem-
onstrate that even when psychoanalysts and behavior
therapists treat similar disorders with similar success
rates, the patients differ in many ways.
Patient preferences
Patient preferences have been identified as one of the
three key components of evidence-based medicine, along
with the best available research and clinical expertise.
They can be defined as the behaviors or attributes of the
therapist or therapy that patients value or desire. Re-
gardless of the therapeutic model, engaging patients to
become active in psychotherapy is a crucial variable [13].
Patient preferences are particularly important in psycho-
analytic long-term therapies with chronically, severely ill
patients who have already undergone several unsuccess-
ful therapies [9].
Role preferences involve the behaviors and activities
that clients desire themselves and their therapists to
engage in while in therapy (for example, preferring the
therapist to take an active advice-giving or a listening
role, preferring a group or an individual format). Ther-
apist preferences entail characteristics that clients hope
their therapists will possess (for example, extended
clinical experience, similar ethnic background). Treat-
ment preferences include specific desires for the type
of intervention that will be used (for example, a be-
havioral or a psychodynamic approach, psychotherapy
or pharmacotherapy).
A recent meta-analysis [14] of 35 studies found that
patients who were matched to their preferred treatment
were less likely to drop out (OR=0.59; P<0.001) and
showed greater improvement (d=0.31; P<0.001). Type
of preference (role, therapist, treatment) had no specific
effect, but type of design was a significant moderator
with greatest effects in RCTs. Assignment by chance
may or may not meet a patient’s preference. Patients
with strong preferences may refuse randomization and
therefore threaten the external validity of an RCT.
Therefore, we decided to use a complex controlled de-
sign with a patient’s preference arm (assignment of
patients according to their treatment preference) and a
randomization arm (assignment of patients by chance).
Thus, we are able to include patients who refuse
randomization. However, to articulate preferences,
patients need to know the alternatives. Even patients
who have already undergone psychotherapy are often
unable to specify what specific form of treatment they
had, for example, both PAT and CBT are described as
some kind of talking cure. To capture patients’ prefer-
ences, we provided all patients with brief descriptions of
both treatments offered in this trial before their deci-
sions for preference of randomization.
Methods
Study centers
The study is carried out at the following clinical sites:
the Sigmund Freud Institute at Frankfurt, the Depart-
ment of Psychology at the Frankfurt University, the De-
partment of Psychosomatic Medicine and Psychotherapy
at University Medicine Mainz, the Department of Psych-
ology at the University of Mainz, the Department of Psy-
chosomatic Medicine and Psychotherapy at the
University Clinic Hamburg-Eppendorf, the Department
of Psychosomatic Medicine at University Clinic Benja-
min Franklin and clinics in the Theodor-Wenzel-Werk
Berlin, and the Department of Psychology at the Free
University Berlin. These sites are responsible for screen-
ing, information, and independent assessment of all
patients treated by licensed psychotherapists (PAT or
CBT), either in an outpatient unit or in private practice.
We have taken care to include different areas of Ger-
many (middle, and north) and institutions, in order to
include a broad range of patients and therapists. The
Department of Psychology at the University of Tübingen
is responsible for CBT training and supervision at all
clinical sites. The center for documentation, statistics,
and data analyses at the Ludwig-Maximilians University
Munich is an independent site that performs data moni-
toring, randomization, and statistical evaluation. Patients
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practice. In all cases, assessments are conducted by inde-
pendent, trained, and supervised clinicians, who are
blind to the intervention.
Participants
We include patients between 21 and 60 years of age suf-
fering from chronic depression. Patients have to be
depressed for more than one year and currently meet a
diagnosis of major depression or dysthymia. In addition,
their current depression has to be of a certain severity,
meeting a Beck Depression Inventory (BDI - self-report)
score above 17 and aclinician-rated Quick Inventory of
Depressive Symptoms (QIDS-C) score of more than 10
points. These inclusion criteria and the exclusion criteria
are listed in Table 1. Patients can be on antidepressant
medication but still meet the inclusion criteria. Patients
on medication have to be on a stable dosage for more
than four weeks. After information and discussion of the
study protocol, the required assessments over three
years, and the study interventions, patients have to sign
an informed consent sheet before starting baseline as-
sessment and either preferred or randomized treatment.
Intervention: psychoanalytic therapy
Psychoanalytic psychotherapeutic and psychoanalytic
strategies are well developed for severely and chronically
depressed patients with comorbid conditions [15-18].
Psychoanalytic authors always consider depression in the
context of developmental processes, particularly patho-
logical processes determined by unconscious fantasies
and conflicts (a) concerning a differentiated, integrated,
and realistic basic feeling of self and identity; (b) con-
cerning the ability to engage in satisfying reciprocal
interpersonal relationships; and (c) concerning the ability
to unfold one’s own creativity in work, developmental
tasks matching the patient’s lifecycle, and satisfying man-
agement of everyday life situations. Discovering the un-
conscious determining factors due to failures in the
development (archaic unconscious fantasies stimulated
by traumatizations, pathological relationships, burdened
life situations, etc.) and working through idiosyncratic
unconscious fantasies and conflicts due to developmen-
tal deficits and traumatizations in the ‘here and now’ of
the therapeutic relationship is seen as indispensable for
a long-lasting change of depressive symptoms. Thus, dif-
ferent forms of depression are not understood as clearly
distinct entities due to specific genetic or neurobio-
logical factors, but as products of complex interactions
between genetic vulnerabilities and experiences in early
relationships leading to pathological fantasies, develop-
ments, and adaptations. They constitute maladaptive
attempts of the individual to cope with severe and last-
ing disruptions of his normal development.
All psychoanalytic study therapists were trained in the
Tavistock manual for treating chronic depressed patients
[18] in a workshop. This manual details psychoanalytic
techniques to be applied with this group of patients, illu-
strated by clinical ‘anchor examples’. Pretested in a Brit-
ish trial with chronically depressed patients, it specifies a
therapeutic approach, including establishing emotional
contact, receptivity and openness, identification of fears,
activity, and work in the ‘here and now’ and in transfer-
ence. A psychodynamic model of the evolvement of
chronic depression provides a background of specific
interventions. Participating psychoanalysts have had at
least three years of clinical practice, participate in regular
supervision groups, and record at least 30 therapy ses-
sions, to permit independent control for adherence and
competence.
Table 1 Inclusion and exclusion criteria
Inclusion criteria ▪Diagnosis of major depression or dysthymia (based on Structured Clinical Interview - SCID) for at least 12 months
▪QIDS-C score >10; BDI 2 >17
▪Complaints for at least 12 month
▪Age: 21 to 60 years
▪Sufficient knowledge of the German language
▪Informed consent with the study protocol
Exclusion criteria ▪Current or past psychotic symptomatology, schizoaffective, schizophrenic, or bipolar affective disorder
▪Substance dependence current or during the last three years
▪Dementia
▪Borderline, schizotypal and antisocial personality disorder
▪Acute suicidality
▪Restriction of intellectual capacity
▪Serious physical illness that strongly affects the depression or is causal for the depression
▪Concurrent psychotherapeutic treatment
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Cognitive and behavior therapy for depression was
developed by Beck, Rush, Shaw, and Emery [19] and
Lewinsohn, Munoz, Youngren, and Zeiss [20]. Their
manuals are adapted and integrated in a widely used and
well-accepted CBT for depression [21]. Nearly all
licensed behavior therapists are familiar with this manual
and material, and have received formal training in using
the manual. In general, CBT with depressed patients fol-
lows five phases within 25 to 45 sessions:
 Phase 1: Development, biographical information,
problem analysis, goals, psychoeducation, rationale
for treatment, explanation of intervention steps.
 Phase 2: Behavior oriented interventions, activation,
increasing pleasant activities, balance of negative and
positive activities, situation analysis, structuring day
and week.
 Phase 3: Cognitive interventions, thought control,
focus on automatic thoughts and alternatives,
influence basic assumptions and schemata.
 Phase 4: Skill training, social skills, problem-solving
skills, communication skills, role play, stress
management, etc.
 Phase 5: Maintenance, prepare for crisis and
beginning depression, relapse prevention, transfer
into everyday life.
This basic CBT for depression can be extended for
chronic depressed patients by intervention elements and
strategies (for example, situational analysis, skill training,
disciplined self-disclosure) of cognitive behavioral system
of psychotherapy [22]. All the study CBT-therapists are
well trained and state licensed. They see patients regu-
larly, either in their own private practice or as therapists
in cooperating outpatient units. Furthermore, they all
participated in an initiating workshop about CBT of
chronic depression and were supervised throughout the
study. Supervision was offered at each site by experi-
enced senior behavior therapists. In addition, at each
site, additional workshops about CBASP or MBCT, or
both, were held for the study therapists. Each therapy
session is taped and a selection of tapes of each therapy
will be rated to control for adherence to cognitive behav-
ior therapy and for therapists’ competence.
Assessments
The time points of assessment and the measures are
presented in Table 2. Assessment is conducted before as-
signment to treatments, and over a course of three years.
Patients are assessed (structured clinical interview,
SCID; quick inventory of depressive symptoms, QIDS)
by independent and trained clinicians, who are blind to
treatment conditions. We took great care to characterize
patients by psychoanalytically oriented characteristics of
psychic structure and conflict [23-25].
Objectives and hypotheses
The purpose of the trial is to address the following
issues:
▪ Short- and long-term efficacy of the two treatments
(PAT, CBT).
▪ Course and stability of treatment effects.
▪ Impact of randomization compared with preference
for both treatments.
▪ Health costs (work loss, hospitalization, outpatient
treatment, drugs, etc.).
Hypotheses
A. Effectiveness and comparison of the two treatments
with the chronically depressed:
Both psychotherapies lead to positive effects
concerning (a) the reduction of depressive
symptoms (QIDS, BDI), (b) the proportion of
remitted patients (LIFE), (c) improved social
functioning (SOFAS), (d) a decrease of continuous
antidepressant medication. These effects are
manifested at the main assessments (see Table 2: t4,
t6, t8) a cross the trial.
The courses of change differ between PAT and CBT:
(a) CBT achieves faster symptom reduction, (b) PAT
starts slowly but achieves more stable, lasting
effects (this is evidenced in the process measures,
the rates of response and the symptom level at
follow-up (see Table 2: t6, t8, t10).
B. Comparison of preferred and randomized therapies:
Preferred therapies are expected to lead to stronger
effects and less study drop-outs than randomized
therapies.
Patient preference is particularly important in PAT.
Therefore, we expect larger effect differences
between PAT preference and PAT randomization
compared with CBT.
C. Health costs and cost effectiveness.
We expect a significant reduction of the days of
absence from work and of further treatment needed
(for example, hospitalization) for both therapies.
We expect larger health-cost reductions for PAT
compared with CBT in the long term.
We expect that treatment costs for CBT will be
lower than those for PAT, resulting in a better cost-
benefit ratio.
Design
The trial will include about 360 chronically depressed
outpatients. About 180 patients will have a clear
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ment (t0) they will be assigned to a study therapist
offering the preferred intervention. About 180 patients
will come without preference and accept to be rando-
mized to either PAT or CBT. Randomization will take
place after baseline assessment (t0). Figure 1 sum-
marizes the 2 (preference) by 2 (psychotherapies) by 4
(time) factorial design.
Outcome
The primary outcome measures are the Quick Inventory
of Depressive Symptoms (QIDS [26]) (independent clin-
ician rating) and the Beck Depression Inventory (BDI-2)
one year after initiation of treatment (t4). Treatment re-
sponse is defined as a decline of at least 50% from t0
(baseline, pre-treatment) to t4 (12 months after intake.
Remission is defined by a QIDS-score below 6. A relapse
Table 2 Planned assessments in the course of the trial (t7 to t10 are options for extension, depending on funding)
Measure point Patient Therapist Diagnostician
t0 intake BDI-2, SCL90-R, DAS, DEQ, CTQ, IIP SKID I/II, QIDS-C, OPD-2, HUS, SRS, SOFAS
t1 (weekly, weeks 1–6) QIDS-S, HAQ QIDS-C, HAQ
t2 (3 mo) QIDS-S, HAQ QIDS-C, HAQ
t3 (6 mo) QIDS-S, HAQ QIDS-C, HAQ
t4 main assessment (12 mo) BDI-2, SCL-90R, DAS, DEQ, IIP, HAQ QIDS-C, HAQ LIFE, QIDS-C, OPD-2, HUS, SRS, SOFAS
t5 (18 mo) QIDS-S, HAQ QIDS-C, HAQ
t6 main assessment (24 mo) BDI-2, SCL-90R, DAS, DEQ, IIP, HAQ LIFE, QIDS-C, HUS, SRS, SOFAS
t7 (30 mo) QIDS-S, HAQ QIDS-C, HAQ
t8 main assessment (36 mo) BDI-2, SCL-90R, DAS, DEQ, IIP, HAQ QIDS-C, HAQ LIFE, QIDS-C, OPD-2, HUS, SRS, SOFAS
t9 main assessment (48 mo) BDI-2, SCL-90R, DAS, DEQ, IIP, HAQ LIFE, QIDS-C, HUS, SRS, SOFAS
t10 final assessment (60 mo) BDI-2, SCL-90R, DAS, DEQ, IIP, HAQ LIFE, QIDS-C, OPD-2, HUS, SRS, SOFAS
Notes: BDI 2 Beck Depression Inventory II, CTQ Childhood Trauma Questionnaire, DAS Dysfunctional Attitude Scale, DEQ Depressive Experience Questionnaire,
HAQ Helping Alliance Questionnaire (patient-, therapist-form), HUS Heidelberger Restructuring Scale, IIP Inventory of Interpersonal Problems, LIFE Longitudinal
Follow-up Evaluation, OPD-2 Operationalized Psychodynamic Diagnostics, PEI Psychoanalytic Intake Interview, QIDS Quick Inventory of Depressive Symptoms
[self- (QIDS-S) and clinician-rating (QIDS-C)], SCID I, II Structured Clinical Interview according to DSM-IV, SCL-90R Symptom-Checklist, SOFAS Social functioning,
SRS Self-Reflective Functioning Scale.
360 patients being 
depressed for more than one 
year and giving informed 
consent to participate in the 
study  
180 patients with clear 
preference either for PAT or 
CBT. Assigned to preference 
180 depressed patients without 
preference and accept to be 
randomized either to PAT or to 
CBT.
90 CBT 
patients 
90 PAT 
patients
90 CBT 
patients
90 PAT 
patients 
ITT-level
ATP- level 
60 CBT 
patients 
60 PAT 
patients
60 CBT 
patients
60 PAT 
patients 
Figure 1 Study design (projected numbers).
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order (MDD) are fulfilled, for example, a QIDS-score
above 9 is documented or hospitalization or outpatient
treatment are needed.
Secondary outcome measures include the Beck De-
pression Inventory (BDI 2 [27]), the QIDS-self-rating,
the Symptom-Checklist (SCL-90R [28]), the Depressive
Experience Questionnaire (DEQ [29]) and the Dysfunc-
tional Attitude Scale (DAS [30]). Furthermore, we assess
social functioning (SOFAS [31]), the Helping Alliance
Questionnaire (HAQ [32], and recurrence of depressive
episodes assessed by the longitudinal follow-up evalu-
ation interview (LIFE [33]).
Sample size calculation
Sample size calculation was based on meta-analyses with
similar interventions in similar patient groups using
similar outcome instruments [10,11,34,35]. Based on the
Hamilton Depression Rating Scale (a 17-item clinician
rating form, similar to the QIDS-C) we expect pre-post
effect sizes for psychotherapies of depression of d=1.2.
A study including a direct comparison of PAT and CBT
is not available. Therefore, we used meta-analysis of
comparing psychotherapy with psychiatric therapy with
depressed out-patients to extrapolate a probable effect
size of d=0.50 between treatments of different efficacy
at post-treatment. To detect this difference at α = 0.025
(two-tailed) with a power of 0.80, a minimum number of
60 patients per cell are required (see Figure 1).
Secondary analyses
Self-report questionnaires and observer ratings will be
analyzed by mixed models with repeated measurements.
With two co-primary outcomes, we will conduct the
tests at a 0.025 level of significance (two-tailed) to adjust
for the multiple comparison issue. Further analyses will
include cross-sectional analyses to compare therapists;
subgroup analyses of subjects’ and therapists’ conditions;
and costs of the SP treatment.
Descriptive statistics showing the measurements over
time will be presented whenever appropriate. Serious ad-
verse events and cases of drop-outs will be analyzed
descriptively.
Randomization
As Figure 1 shows, in a partial randomization preference
trial, patients are asked if they have a preference for one
specific treatment (PAT or CBT). Treatments are out-
lined to them in terms of a general description (see box
for the instructions). If they articulate a specific prefer-
ence, they are assigned accordingly (preference arm). If
they articulate no specific preference, they are rando-
mized (randomization arm).
Statistical analysis
The design is an analysis of variance design with
repeated measures: The main factor is the form of treat-
ment (CBT or PAT) and assignment (preference or
randomization). Four main assessments encompass the
treatment phase and follow-up. The variability of intake
symptoms is controlled as a covariate. To determine the
time factor, ANCOVAs with repeated measures and
linear regression with autocorrelated data (compound
symmetric covariance structure models) are applied.
Dichotomous response scores are examined by tests
for frequency distributions and procedures of survival
analysis (Coxregression, log-ranktests). It is also tested
whether differences between CBT and PAT depend on
assignment (preference vs. randomization), that is, if a
naturalistic selection brings clearer differences than
random assignment.
Safety aspects
Safety parameters will comprise newly occurring psychi-
atric diagnoses (LIFE) and all serious adverse events that
are reported during and up to six months after
treatment.
Medical complications
The recording of adverse events will be restricted to psy-
chological conditions. Formally, these are defined as any
disorder classified by the International Classification of
Diseases F00 to F99. A serious adverse eventis an ad-
verse event that may occur at any time of the treatment
phase or up to six months after the end of treatment,
that: results in death; is life-threatening; requires subject
hospitalization or prolongation of existing hospital-
ization; results in persistent or significant disability or
incapacity; or is a congenital anomaly or birth defect.
Any adverse event (according to the study specific def-
inition) reported by the subject or detected by the local
investigator will be collected during the trial and must
be documented in the CRF. The local investigator will
use ICD-10 to code the event. The clinical course of the
adverse event will be followed until it has changed to a
stable condition or until the end of follow-up phase,
whichever comes first. In case of serious adverse events,
the Ethics Committee and Data Monitoring Safety Board
(DMSB) will be informed within 24 hours of the serious
adverse event becoming known.
Ethical issues
The final study protocol and the final version of the
written informed consent form were approved by the
Ethics Committee of the Federal State of Rhineland Pal-
atine in Germany (ref: 837.124.075659). The procedure
set out in this protocol, pertaining to the conduct, evalu-
ation, and documentation of this trial, were designed to
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good clinical practice and the ethical principles
described in the current revision of the Declaration of
Helsinki. The trial will be carried out in keeping with
local legal and regulatory requirements. Before being
admitted to the clinical trial, patients must consent to
participate after the nature, scope, and possible conse-
quences of the clinical trial have been explained in a
form understandable to them. The patients must give
written informed consent to participate in the study,
including their consent to publish.
Discussion
This trial has the major goals: (1) to determine the ef-
fectiveness of the two long-term treatments (PAT, CBT)
reimbursed in the German healthcare system for chronic
depression, and (2) to compare the effects of treatment
preference against randomization. It combines the vir-
tues of a randomized controlled (efficacy) trial and a nat-
uralistic approach.
As recent meta-analyses have shown, the treatment of
depression by short-term treatments has been plagued
by high relapse rates and a lack of lasting effectiveness.
Long-term PAT and CBT, however, are not easy to com-
pare, as they differ in frequency (one to three sessions
per week), total number of sessions, and duration of
treatment (one to three years). We therefore tried to
reach comparable doses in the first year of treatment.
Initially, psychoanalysts often work with low frequency
(≤2 sessions per week) with depressed patients; thus
there could be 45 sessions of CBT and up to 80 sessions
of PAT in the first year. As our primary outcome is mea-
sured at one year (t4), doses of treatment can be com-
pared. When psychoanalytic treatment is continued after
one year, dose can be adjusted according to patient need
and treatment process. As CBT entails relapse preven-
tion, there will also be an extended treatment duration.
In any case, number and timing of sessions will be docu-
mented. In this trial, a high quality is assured by an inde-
pendent assessment.
While patient preferences form one of the three key
components of evidence-based medicine, studies on the
impact of patient preference on outcome have been
scarce. Our design enables us to determine the impact
of patient preference on outcome, and we expect a lower
attrition rate and a higher effectiveness for preferred vs.
randomized assignment.
As this trial has been funded substantially by the Ger-
man Society for Psychoanalysis, Psychotherapy, Psycho-
somatics, and Depth Psychology (DGPT), a great effort
was made to counteract allegiance effects. The study also
is financially supported by the independent, medically
oriented Heidehof Foundation (part of the well known
Robert Bosch Foundation, Stuttgart). One of the
principal investigators (MH) is a renowned cognitive be-
havior therapist. Data collection, monitoring, and ana-
lysis are performed by an independent statistician (BR).
Trial status
Ongoing recruitment.
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